Corporate social responsibility, condition branding and ethics in marketing by Hall, Danika & Jones, Sandra C
University of Wollongong 
Research Online 
Faculty of Health and Behavioural Sciences - 
Papers (Archive) Faculty of Science, Medicine and Health 
2008 
Corporate social responsibility, condition branding and ethics in marketing 
Danika Hall 
University of Wollongong, danika@uow.edu.au 
Sandra C. Jones 
University of Wollongong, sandraj@uow.edu.au 
Follow this and additional works at: https://ro.uow.edu.au/hbspapers 
 Part of the Arts and Humanities Commons, Life Sciences Commons, Medicine and Health Sciences 
Commons, and the Social and Behavioral Sciences Commons 
Recommended Citation 
Hall, Danika and Jones, Sandra C.: Corporate social responsibility, condition branding and ethics in 
marketing 2008, 81-88. 
https://ro.uow.edu.au/hbspapers/1666 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Corporate social responsibility, condition branding and ethics in marketing 
Abstract 
Over the past two decades there has been increased interest in corporate responsibility (CSR) and its 
relation to marketing practice and theory )Maignan and Ferrell, 2004: Polonsky and Jevons, 2006). This 
paper explores another marketing phenomena emerging from the pharmaceutical industry: condition 
branding (Angelmar, Angelmar and Kane, 2007: Parry, 2003). Condition branding has been positioned as a 
form of CSR for the industry, in that it provides education to the general public regarding diseases or 
conditions. However, the ethical nature of condition branding has been questioned as it is also seen as a 
deliberate method of increasing markets for pharmaceutical products. This paper raises concerns of 
consumers and regulators regarding condition branding and disease advertising, and suggests how these 
practices could be better regulated or modified to reflect the principles of CSR. 
Keywords 
Corporate, social, responsibility, condition, branding, ethics, marketing 
Disciplines 
Arts and Humanities | Life Sciences | Medicine and Health Sciences | Social and Behavioral Sciences 
Publication Details 
Hall, D. & Jones, S. C. (2008). Corporate social responsibility, condition branding and ethics in marketing. 
In D. Spanjaard, S. Denize & N. Sharma (Eds.), Proceedings of the Australian and New Zealand Marketing 
Academy Conference (pp. 81-88). Sydney, Australia: Australian and New Zealand Marketing Academy. 
This journal article is available at Research Online: https://ro.uow.edu.au/hbspapers/1666 
   1 
Corporate Social Responsibility, Condition Branding and Ethics in Marketing 
 




Over the past two decades there has been increased interest in corporate social responsibility 
(CSR) and its relation to marketing practice and theory (Maignan and Ferrell, 2004; Polonsky 
and Jevons, 2006). This paper explores another marketing phenomena emerging from the 
pharmaceutical industry: condition branding (Angelmar, Angelmar and Kane, 2007; Parry, 
2003). Condition branding has been positioned as a form of CSR for the industry, in that it 
provides education to the general public regarding diseases or conditions. However, the 
ethical nature of condition branding has been questioned as it is also seen as a deliberate 
method of increasing markets for pharmaceutical products. This paper raises concerns of 
consumers and regulators regarding condition branding and disease advertising, and suggests 





While the term Corporate Social Responsibility (CSR) was coined in the 1950s, the concept 
has its roots in social contract theory dating back to 1600s (Langer, 2006). CSR has been 
described as an organisation’s social obligation: to pursue policies, make decisions or take 
actions that are in line with societal objectives and values (Abratt and Sacks, 1988; Robin and 
Reidenbach, 1987). More recently, CSR has been considered in relation to the groups or 
stakeholders that are directly or indirectly affected by the activities of the organisation, such 
as employees, customers, shareholders, suppliers and the local community (Langer, 2006; 
Maignan and Ferrell, 2004). The benefits of CSR for an organisation can include increased 
customer loyalty, employee commitment, supplier support and improved corporate reputation 
(Maignan, Ferrell and Ferrell, 2005). CSR can be seen as part of a greater change in corporate 
philosophy and practice over the past two decades: the business ethics movement (Weber, 
2006). Weber (2006) refers to the mantra “good ethics is good business” which implies that 
“following high ethical standards is related to – and contributes to – business success” (p.15). 
Within this movement it is recognised that ethical and socially responsible behaviour can give 
organisations a competitive advantage, whereas behaviour that creates suspicion or is 
seemingly contradictory to the organisation’s purpose can reduce the chance of business 
success (Abratt and Sacks, 1988).  
 
Over the past decade, disease awareness advertisements sponsored by pharmaceutical 
companies have become increasingly prevalent (Mintzes, 2006a). In the US and Canada, these 
are commonly referred to as ‘help seeking advertisements’ (Food and Drug Administration, 
2004; Mintzes, 2006b), whereas in the UK they are referred to as ‘disease awareness 
campaigns’ (Carpenter, 2003). These advertisements or campaigns usually focus on a disease 
or condition and provide information on symptoms or a range of treatments without 
mentioning a specific product or brand. They usually refer consumers to websites or other 
information sources, or encourage them to speak with their doctor. For example, a Pfizer 
advertisement regarding Alzheimer’s disease has appeared in Reader’s Digest Magazine in 
Australia, with a list of potential symptoms and the statement “If you recognise any of these 
signs or symptoms, check with your doctor” (Pfizer Australasia Pty Ltd, 2004). Disease 
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awareness advertisements such as these can be considered as a component of a new and 
broader marketing strategy within the pharmaceutical industry: ‘condition branding’. 
 
In a recent article, Angelmar, Angelmar and Kane (2007) propose that the pharmaceutical 
marketing paradigm be broadened to include the building of strong condition brands. They 
define condition branding as “the deliberate management of patient, physician, payer and 
other stakeholder knowledge about a condition in order to improve how the condition is 
treated” (p342). This definition suggests that all stakeholders are considered important 
audiences in condition branding and that the over-riding motivation is improving treatment. It 
also suggests that condition branding is a form of socially responsible behaviour for the 
pharmaceutical industry. In a discussion regarding why companies should invest in condition 
branding, the authors state that, aside from increasing sales and raising the total number of 
prescriptions, it could be “for ethical reasons, or because they see image benefits” (Angelmar 
et al., 2007 p. 348). The idea of pharmaceutical marketing practices as a function of 
improving corporate credibility or reputation has previously been suggested with regard to 
disease awareness advertising as well as direct-to-consumer advertising (DTCA) for 
prescription medicines (see for example Bonaccorso and Sturchio, 2002; Carpenter, 2003; 
Wielondek, 2005). However Parry (2003) positions condition branding more purely as a 
profit-motivated function. He suggests that “if you can define a particular condition and its 
associated symptoms in the minds of physicians and patients, you can also predicate the best 
treatment for that condition” (p.43). Parry (2003) identifies three strategies in condition 
branding: increasing the importance of a disease; re-defining or reducing stigma relating to a 
disease; or developing a new condition to create recognition of an unmet need, then 
introducing the product to meet that need.  
 
Based on these descriptions in the marketing literature, it can be considered that the 
motivation for condition branding and producing disease awareness campaigns for 
pharmaceutical companies is three-fold:  
1. Increasing the market: create a sense of need for a product (category need) by 
generating greater knowledge, acceptance or significance of a condition/disease 
2. Increasing product awareness: create greater association between the company’s 
pharmaceutical product and the condition it is designed to treat in the minds of 
prescribing doctors as well as consumers (with a view to increasing prescriptions) 
3. Increasing corporate credibility: position the manufacturer as a socially responsible, 
trustworthy organisation contributing to the education of consumers and other 
stakeholders in an effort to improve early diagnosis and/or treatment of 
conditions/diseases. 
 
One of the few published empirical studies of disease awareness campaigns was documented 
by t’Jong, Stricker and Sturkenboom (2004) and reports on a campaign sponsored by 
pharmaceutical company Novartis in the Netherlands that created awareness and heightened 
the importance of a relatively benign foot fungal condition known as onychomycosis. The 
study found that as a result of the campaign prescription rates for terbinafine (a product made 
by Novartis to treat onychomycosis) and onychomycosis-related consultations increased, 
while prescriptions for the competitor product decreased. t’Jong et al (2004) were critical of 
the impact of the campaign on the workload of doctors and state that the Dutch Society of 
General Practitioners (GPs) opposed the campaign as “an unnecessary focus on an 
unimportant health problem” (p. 931). As such, this condition branding by Novartis achieved 
increased awareness of a product, as well as increased prescriptions, however it failed to 
increase corporate credibility. As a result of the campaign, some GPs in the Netherlands 
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called for a ban on Novartis products (Sheldon, 2002). Novartis has also been criticised in 
Australia (Hall and Jones, 2007a), the US (Langreth and Herper, 2006), and the UK (Jackson, 
2003) for similar campaigns. This leads us to consider whether condition branding, and 




Recent perspectives of CSR consider that the corporation is obligated to consider the groups 
or actors that are directly or indirectly affected by the activities of that corporation, such as 
employees, customers, shareholders, suppliers and the local community (Langer, 2006; 
Maignan and Ferrell, 2004). As part of this approach, organisations adopt a perspective in 
their strategic planning and operational processes which serves to maximise positive impacts 
and minimise negative impacts on stakeholders. In the pharmaceutical industry, stakeholders 
include stockholders, suppliers, contractors, employees, patients, doctors, other healthcare 
professionals, medical journal editors, clinical researchers, medical educators, healthcare 
payers, healthcare policy makers, and people who need but do not have access to 
pharmaceutical products (Weber, 2006). The following section, however, will only consider 
the practices of condition branding and disease awareness advertising in relation to two 
stakeholder groups: consumers (including consumer organisations and public health 
advocates) and regulators (government or industry bodies). 
 
Consumers 
In reviewing literature regarding condition branding and disease awareness campaigns, it 
appears that consumers are concerned that such campaigns will only focus on diseases where 
there are large and lucrative markets, for example lifestyle conditions such as obesity and 
hair-loss (Consumers International, 2006; Glatter, 2004). This has been the case for the 
practice of DTCA, as content analyses of US magazines have found the most advertised 
products were for chronic, non-life-threatening diseases or lifestyle choices (Holmes and 
Desselle, 2004; Roth, 1996). A recent Australian survey found that consumers most 
commonly recalled seeing advertisements in the mass media for erectile dysfunction and 
weight loss (Hall and Jones, 2007b). There is further concern that these practices can 
exaggerate the risk or prevalence of a condition (Mintzes, 1998; Mintzes, 2006a) and that this 
may result in increased community fear and anxiety and unnecessary visits to doctors. A 
recent example is an Australian disease awareness campaign for genital herpes which stated 
that “one in 8 of us … have genital herpes”, however the image was six female symbols, two 
of which were highlighted red, visually suggesting that one third of Australian women have 
genital herpes (GlaxoSmithKline, 2006). 
 
Additionally, there is concern when condition branding and disease awareness advertising 
utilises persuasive techniques to encourage consumers to identify with symptoms such that 
they may begin to consider normal events (such as mood fluctuations or daily frustrations) as 
part of a serious health problem (such as a psychiatric disorder) which requires medical 
treatment (Moynihan and Cassels, 2005). Examples include the advertising of Pre-menstrual 
Dysphoric Disorder (an extreme form of Pre-menstrual tension) in the US, and the promotion 
of Social Anxiety Disorder or Social Phobia (an extreme form of shyness) in the US and 
Australia (Moynihan and Cassels, 2005). An artist recently received some recognition for a 
parody on pharmaceutical companies medicalising normal life experience (often referred to as 
‘disease mongering’). Her campaign for a ‘new’ disorder known as Dysphoric Social 
Attention Consumption Deficit Anxiety Disorder with symptoms including stress and weight-
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gain, coincided with the launch of a ‘new’ pharmaceutical product, Havidol, and was 
complete with faux television and print advertisements as well as a website (Burke, 2007). 
 
Regulators 
In countries where DTCA of prescription medicines is not allowed - including Australia, 
Canada, the European Union and the UK - pharmaceutical companies are prohibited from 
advertising prescription products directly, but can sponsor disease awareness advertisements. 
These advertisements often fall under the regulation of pharmaceutical industry bodies (self 
regulation). Such is the case in Australia, where Medicines Australia’s voluntary Code of 
Conduct prohibits advertising branded prescription medicines (in keeping with the 
Therapeutic Goods Act 1989) but allows for ‘patient education’ (Medicines Australia, 2006).  
Patient education is described as educational information on medical conditions and the range 
of treatments that may be prescribed by a doctor (Medicines Australia, 2006).  
 
Of concern for regulators is when pharmaceutical companies use disease awareness 
campaigns to directly promote their products to consumers under the guise of education, and 
evade the ban on DTCA (Gardner, Mintzes and Ostry, 2003; Mintzes, 2006a). There is 
increasing evidence of pharmaceutical companies using branding techniques (such as special 
fonts, colours, logos, campaign names and spokes-characters) to create pseudo brands without 
actually naming the product, and via advertising they create an association between their 
product and a condition/disease (Hall and Jones, 2007a), for example recent advertisements 
featuring a tiger character that is synonymous with Viagra. In some instances, these 
advertisements provide limited disease information but encourage patients to ask their doctor 
about new available treatments. There is also evidence that disease advertising directed at 
consumers occurs concurrently with branded campaigns targeting doctors so that doctors can 
recall (and potentially prescribe) the product when patients discuss the disease advertisement 
with them (Glatter, 2004; Mackenzie et al., 2007).   
 
Some of these issues, and the consumer concerns described above, have been considered by 
the Australian Government in a National Competition Review of Drugs, Poisons and 
Controlled Substances Legislation (Galbally, 2000). The concern that some disease awareness 
advertisements convey limited educational information, and use branding techniques to 
convey a product identity, have also been noted by the Medicines Australia Complaints 
Committee  - see deliberations of complaints 676 and 767 in Code of Conduct Annual 
Reports (Medicines Australia, 2003; Medicines Australia, 2005). Medicines Australia have 
the opportunity to redress some of these concerns by stipulating more specific and detailed 
guidelines regarding what constitutes disease awareness advertising or patient education. 
Other countries, including the UK’s Medicines and Healthcare Products Regulatory Agency 
and the Pharmaceutical Research and Manufacturers Association in the US, have developed 
detailed guidelines relating to this form of advertising (MHRA, 2003; PhRMA, 2005).  
 
Corporate social responsibility and ethical marketing 
 
Within the pharmaceutical industry there is belief that condition branding and disease 
awareness advertising is a form of CSR, because it provides consumer education that may 
lead to early diagnosis and treatment, with potential for other public health benefits 
(Angelmar et al., 2007; Wielondek, 2005). It has been argued that because ill health is one of 
the most tangible forms of suffering, the pharmaceutical industry often believes it can link its 
marketing activities to ethical objectives (Applbaum, 2006). However, Parsons (2007) has 
examined condition branding as a communication strategy against the ‘Five Pillars of Public 
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Relations Ethics’: the objective to do no harm; the objective to do good; telling the truth; 
maintaining privacy; and fairness and social responsibility. She found that condition branding 
failed against each of the pillars, with the exception of maintaining privacy, and concluded 
that disease branding is an unethical marketing communication strategy (Parsons, 2007).  
 
In a review of pharmaceutical marketing in Europe, Consumers International (2006) describe 
that disease awareness advertising is often disguised as CSR, because it creates consumer 
demand for drugs for pharmaceutical products, while giving consumers a sense of trust in the 
advertisers. Polonsky and Jevons (2006) state that CSR should reflect the core value of 
activities and strategic direction of corporations, and that it should not be an illusive method 
to improve corporate image or achieve differentiation. Robin and Reidenbach (1987) discuss 
the concept of CSR being congruent with marketing objectives – as would be anticipated by 
consumers. They argue that “all of the parts must fit together to produce a logical, internally 
consistent and easily communicated ethical profile” (page 54).  Pharmaceutical companies 
engaging in condition branding, and framing it as a form of CSR, run the risk of creating 
considerable consumer skepticism and, as a consequence, reduced corporate credibility. 
However, companies also have the opportunity to be upfront regarding the purpose of their 
advertising, such as including some form of generic disclosure that the advertisers make 
product(s) to treat or prevent the condition advertised. 
 
If industry sponsored disease awareness advertisements were to be considered as a form of 
CSR, it would be important that the sponsors provide balanced and accurate information 
regarding important diseases other than those that they produce a treatment for. Wielondek 
(2005) provides an overview of the declining corporate image of the pharmaceutical industry 
and the negative impacts of product recalls and DTCA in the US. She suggests that disease 
awareness campaigns provide an opportunity for the pharmaceutical industry to regain 
corporate credibility if they are carefully planned and implemented to minimise negative 
effects. She proposes the opportunity for a disease awareness advertising campaign 
promoting, for example, diabetes lifestyle improvement programs, in an effort to regain 
corporate credibility (Wielondek, 2005). There are many other CSR opportunities for 
pharmaceutical companies, including those unrelated to advertising or provision of disease 
information. Ross-Wooldridge et al (2004) describe that pharmaceutical companies can 
become more competitive and develop greater brand equity via socially responsible actions 





Condition branding and disease awareness advertising are marketing practices increasingly 
being used by the pharmaceutical industry, however they have the potential to negatively 
impact upon stakeholders. They could increase consumer fear and anxiety, and unnecessary 
visits to doctors, and regulators may be concerned with how these practices skirt current 
guidelines for the advertising of prescription medicines. While these practices have been 
positioned as a form of CSR within the industry, it is clear that they are at odds with what 
traditionally constitutes CSR. Disease awareness advertising that might constitute CSR is 
where the advertiser does not serve to benefit, such as a non-pharmacological behaviour 
change or prevention campaign. Further research is needed to explore the extent and nature 
of, as well as consumer attitudes towards, condition branding and disease awareness 
advertising in order to determine impacts on stakeholders and to inform future regulation. 
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